Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

Míreanna comhchosúla

• Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
  de réir: Ye Liu, et al.
  Foilsithe / Cruthaithe: (2021-06-01)
• In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
  de réir: Eric Bartee, et al.
  Foilsithe / Cruthaithe: (2017-05-01)
• Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
  de réir: Praveen K. Bommareddy, et al.
  Foilsithe / Cruthaithe: (2019-07-01)
• Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
  de réir: Emily J. Lelliott, et al.
  Foilsithe / Cruthaithe: (2021-05-01)
• Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
  de réir: S. Napolitano, et al.
  Foilsithe / Cruthaithe: (2019-12-01)